ASCO® 2024 Insights: "NETTER-2 Study - Safety & TTR of [177Lu]Lu-DOTATATE in Pts With Newly Diagnosed Advanced Grade 2 & 3, Well-Differentiated Gastroenteropancreatic NETs"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NETTER-2 Study - Safety & TTR of [177Lu]Lu-DOTATATE in Pts With Newly Diagnosed Advanced Grade 2 & 3, Well-Differentiated Gastroenteropancreatic NETs"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Pamela Kunz

43 views

June 12, 2024

Chapters

NETTER-2 Study Overview & Key Differences

00:00

Safety & Time to Response in NETTER-2

01:54

Comments 0

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

2024 ASCO® Annual Meeting Insights Hub: GI Videos

ASCO® 2024 Insights: "Botensilimab + Balstilimab in Microsatellite S…

2024 ASCO® Annual Meeting Insights Hub

A. Bullock

125 views

3 months ago

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

2024 ASCO® Annual Meeting Insights Hub

J. Knox

164 views

4 months ago

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

2024 ASCO® Annual Meeting Insights Hub

C. Eng

203 views

4 months ago

View All

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

7 months ago

Neuroendocrine Tumors: Management and Updates

Integrity CE

R. Iyer

551 views

3 months ago

New

GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

373 views

3 weeks ago

Neuroendocrine Tumors in the GI Tract

Florida Gastroenterologic Society

A. Luthra

991 views

1 year ago

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Sol…

UCSF School of Medicine

H. Kang

2.1K views

1 year ago

Sequencing Systemic Treatments for Well-Differentiated NETs

Integrity CE

J. Strosberg

242 views

7 months ago

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Total Health

A. Grothey

246 views

8 months ago

Neuroendocrine Cancers: Background, Diagnosis, and Current Treatment

Total Health

R. Lentz

192 views

4 months ago

Imaging for Neuroendocrine Neoplasms

North American Neuroendocrine Tumor Society

G. Spilberg

115 views

1 month ago

SWOG S2012: 1L Chemo +/- Atezolizumab in Advanced Extrapulmonary Neu…

Fred Hutchinson Cancer Center

D. Zhen

135 views

3 months ago

MRD in GI Malignancies: Current Clinical Utility of ctDNA

Horizon CME

A. Scott

201 views

5 months ago

ESMO 2024 Summary: Treatment Strategies and Sequencing in Carcinoid …

2024 ESMO Annual Meeting Insights Hub

R. Riechelmann

101 views

1 month ago

ASCO® 2024 Insights: "212Pb-DOTAMTATE, a Targeted Alpha Therapy for …

2024 ASCO® Annual Meeting Insights Hub

J. Strosberg

201 views

5 months ago

NETs 101 and Overview of Medical Management

Yale Cancer Center

P. Kunz

350 views

11 months ago

New Developments in Neuroendocrine Tumor Treatment

Oncology Data Advisor

S. Kareff, A. Chauhan

168 views

8 months ago

Debates in NET Treatment: Surgery vs. IR for Liver-Limited Disease

Integrity CE

E. Liu

171 views

7 months ago

Medical Oncology Updates in NETs

2023 Johns Hopkins Updates in Gastrointestinal Cancers

P. Kunz

409 views

1 year ago

Role of Precision Medicine in the Treatment of Neuroendocrine Neopla…

University of Miami Sylvester Comprehensive Cancer Center

A. Chauhan

72 views

3 months ago

Pancreatic Adenocarcinoma and Neuroendocrine Tumors - An Update

AdventHealth

M. Tejani

83 views

1 month ago

Management of Poorly Differentiated Neuroendocrine Carcinomas

North American Neuroendocrine Tumor Society

J. Chan

88 views

2 months ago

AUTOPLAY

Login

Login

Join VuMedi

ASCO® 2024 Insights: "NETTER-2 Study - Safety & TTR of [177Lu]Lu-DOTATATE in Pts With Newly Diagnosed Advanced Grade 2 & 3, Well-Differentiated Gastroenteropancreatic NETs"

NETTER-2 Study Overview & Key Differences

Safety & Time to Response in NETTER-2

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

2024 ASCO® Annual Meeting Insights Hub: GI Videos

ASCO® 2024 Insights: "Botensilimab + Balstilimab in Microsatellite S…

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

Recommended

Hyperprogression in Cancer Treated With Immunotherapy

Neuroendocrine Tumors: Management and Updates

GI Cancers: Hot Topics in 2024

Neuroendocrine Tumors in the GI Tract

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Sol…

Sequencing Systemic Treatments for Well-Differentiated NETs

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Neuroendocrine Cancers: Background, Diagnosis, and Current Treatment

Imaging for Neuroendocrine Neoplasms

SWOG S2012: 1L Chemo +/- Atezolizumab in Advanced Extrapulmonary Neu…

MRD in GI Malignancies: Current Clinical Utility of ctDNA

ESMO 2024 Summary: Treatment Strategies and Sequencing in Carcinoid …

ASCO® 2024 Insights: "212Pb-DOTAMTATE, a Targeted Alpha Therapy for …

NETs 101 and Overview of Medical Management

New Developments in Neuroendocrine Tumor Treatment

Debates in NET Treatment: Surgery vs. IR for Liver-Limited Disease

Medical Oncology Updates in NETs

Role of Precision Medicine in the Treatment of Neuroendocrine Neopla…

Pancreatic Adenocarcinoma and Neuroendocrine Tumors - An Update

Management of Poorly Differentiated Neuroendocrine Carcinomas